Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for organ sharing registry data

Transplantation

Volumn 90, Issue 12, 2010, Pages 1511-1515

  Cai, Junchao ^a   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

Alemtuzumab; Basiliximab; Campath 1H; Daclizumab; Heart transplantation; Kidney transplantation; Liver transplantation; Lung transplantation; Pancreas transplantation; Rabbit antithymocyte globulin; Simulect; Thymoglobulin; Zenapax

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; DRUG SUBSTITUTION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PANCREAS GRAFT REJECTION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REGISTER; SURVIVAL RATE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; REGISTRIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78650842081     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fecfcb     Document Type: Article

References (19)

1. Hawksworth JS, Leeser D, Jindal RM, et al. New directions for induction immunosuppression strategy in solid organ transplantation. Am J Surg 2009; 197: 515.
2. Kirk AD. Induction immunosuppression. Transplantation 2006; 82: 593.
3. Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: A meta-analysis. J Am Soc Nephrol 1997; 8: 1771.
4. Gjertson DW. Impact of delayed graft function and acute rejection on kidney graft survival. Clin Transpl 2000: 467.
5. Heaf JG, Ladefoged J. The effect of acute rejection on long-term renal graft survival is mainly related to initial renal damage. Transpl Int 1998; 11(suppl 1): S26.
6. Munoz R, Romero B, Medeiros M, et al. Renal graft survival in children with early acute rejection. Pediatr Transplant 1998; 2: 294.
7. Reddy KS, Davies D, Ormond D, et al. Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation. Am J Transplant 2003; 3: 439.
8. Cai J, Terasaki PI. Humoral theory of transplantation: Mechanism, prevention, and treatment. Hum Immunol 2005; 66: 334.
9. Knechtle SJ, Fechner JH Jr, Dong Y, et al. Primate renal transplants using immunotoxin. Surgery 1998; 124: 438; discussion 446.
10. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
11. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
12. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87.
13. Ballen K. New trends in transplantation: The use of thymoglobulin. Expert Opin Drug Metab Toxicol 2009; 5: 351.
14. Ciancio G, Burke GW, Warque ME, et al. Efficacy of alemtuzumab in organ transplantation: Current clinical status. BioDrugs 2006; 20: 85.
15. Henry ML, Rajab A. The use of basiliximab in solid organ transplantation. Expert Opin Pharmacother 2002; 3: 1657.
16. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19: 705.
17. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 2006; 81: 1361.
18. Olyaei AJ, Thi K, deMattos AM, et al. Use of basiliximab and daclizumab in kidney transplantation. Prog Transplant 2001; 11: 33; quiz 38.
19. Wiseman LR, Faulds D. Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999; 58: 1029.